Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC)

Keyphrases

• Peripheral Blood Progenitor Cells 100%
• High-dose Chemotherapy 100%
• Mobilized Peripheral Blood 100%
• Thiotepa 75%
• Cyclophosphamide 50%
• Growth Factors 50%
• Insurance 25%
• Second-line Treatment 25%
• Antitumor Efficacy 25%
• Engraftment 25%
• 2-cycles 25%
• Etoposide 25%
• Melphalan 25%
• Carboplatin 25%
• No Response 25%
• Mitoxantrone 25%
• Chemotherapy Regimen 25%
• Measurable Disease 25%
• First Cycle 25%
• Disease-specific 25%
• Efficacy-toxicity 25%
• Hematologic Recovery 25%
• Patient Refusal 25%
• High-risk Cancer 25%
• Metastatic Risk 25%

Pharmacology, Toxicology and Pharmaceutical Science

• High Dose Chemotherapy 100%
• Thiotepa 75%
• Disease 50%
• Cyclophosphamide 50%
• Growth Factor 50%
• Etoposide 25%
• Melphalan 25%
• Carboplatin 25%
• Mitoxantrone 25%
• Chemotherapy Regimens 25%

Immunology and Microbiology

• Drug Megadose 100%
• Cyclophosphamide 50%
• Growth Factor 50%
• Engraftment 25%